Quaker Chemical Appoints New CFO

Ticker: KWR · Form: 8-K · Filed: Dec 11, 2024 · CIK: 81362

Quaker Chemical CORP 8-K Filing Summary
FieldDetail
CompanyQuaker Chemical CORP (KWR)
Form Type8-K
Filed DateDec 11, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$1
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, cfo

Related Tickers: KWR

TL;DR

Quaker Chemical just named a new CFO, Michael Barry, starting Dec 9th.

AI Summary

Quaker Chemical Corporation announced on December 5, 2024, the appointment of Michael F. Barry as Chief Financial Officer, effective December 9, 2024. Barry will also serve as Executive Vice President. He previously held the role of Senior Vice President, Finance.

Why It Matters

A change in Chief Financial Officer can signal shifts in financial strategy or operational focus for the company.

Risk Assessment

Risk Level: low — This filing reports a routine executive appointment, which typically carries low risk.

Key Players & Entities

FAQ

What is the effective date of Michael F. Barry's appointment as CFO?

Michael F. Barry's appointment as Chief Financial Officer is effective December 9, 2024.

What was Michael F. Barry's previous role at Quaker Chemical?

Prior to his appointment as CFO, Michael F. Barry served as Senior Vice President, Finance.

What other role will Michael F. Barry assume?

In addition to Chief Financial Officer, Michael F. Barry will also serve as Executive Vice President.

On what date was this Form 8-K filed?

This Form 8-K was filed on December 11, 2024.

What is Quaker Chemical Corporation's principal executive office address?

Quaker Chemical Corporation's principal executive offices are located at 901 E. Hector Street, Conshohocken, Pennsylvania 19428.

Filing Stats: 729 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-12-11 16:30:32

Key Financial Figures

Filing Documents

02. Departure of Directors or Certain Officers; Election

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported, Andrew E. Tometich has departed Quaker Chemical Corporation (the "Company") and is no longer serving as the Company's Chief Executive Officer and President or as a member of the Board, effective November 18, 2024. Mr. Tometich's departure was not related to any disagreement between him and the Company. On December 5, 2024, the Company and Mr. Tometich entered into a Separation Agreement and General Release (the "Separation Agreement") related to Mr. Tometich's involuntary termination. Subject to the terms and conditions of the Separation Agreement, Mr. Tometich will be entitled to receive the severance payments and benefits as described in the Company's Current Report on Form 8-K filed on November 20, 2024 and further detailed in the Company's proxy statement filed with the Securities and Exchange Commission on March 28, 2024, with the below modifications. Under the Separation Agreement, Mr. Tometich will also receive accelerated, prorated vesting of any outstanding Stock Options, Restricted Stock Units, Performance Stock Units ("PSUs") and Restricted Stock, in each case, as defined in the Quaker Chemical Corporation 2016 Long-Term Incentive Plan (the "2016 Plan"). Achievement as to Performance Program Targets, as defined in the 2016 Plan, for the various performance-based awards will be measured at the end of the respective performance periods and paid out if earned at that time. PSUs will continue to be paid at the same time that they otherwise would have been paid. The foregoing summary of the Separation Agreement does not purport to be a complete description of all of the terms and conditions of the document and is qualified in its entirety by reference to the full text of the document, which is filed as an exhibit to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. The following exhibits are included as part of this Current Report on Form 8-K: Exhibit No. Description 10.1* Separation Agreement and General Release by and between Quaker Chemical Corporation and Andrew E. Tometich, dated December 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Management contract, compensatory plan or arrangement 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUAKER CHEMICAL CORPORATION Date: December 11, 2024 By: /s/ Robert T. Traub Robert T. Traub Senior Vice President, General Counsel and Corporate Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing